Jean Bienaime Biography and Net Worth

Jean-Jacques Bienaimé was appointed to our Board in November 2023. Mr. Bienaimé has served as the CEO and a member of the board of directors of BioMarin Pharmaceutical Inc.(BioMarin), a biotechnology company focused on genetic discovery, since May 2005, and served as its chairman of the board since June 2015. Mr. Bienaimé served as Chairman, CEO, and President of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics, from November 2002 to April 2005. Prior to Genencor, Mr. Bienaimé served as Chairman, CEO and President of Sangstat Medical Corporation, an immunology-focused biotechnology company, from 1998 to late 2002, becoming President in 1998 and CEO in 1999. Mr. Bienaimé also held several senior management positions at Rhône-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis) from 1992 to 1998, culminating in the position of Senior Vice President of Worldwide Marketing and Business Development. Earlier in his career, Mr. Bienaimé worked at Genentech, Inc. where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks. In addition to being a member of BioMarin’s board, Mr. Bienaimé also currently serves on the board of Incyte Corporation, a public biotechnology company, and he is a member of the boards of Biotechnology Innovation Organization (BIO) and Pharmaceutical Research and Manufacturers of America (PhRMA), both industry trade associations. Mr. Bienaimé received an MBA from the Wharton School at the University of Pennsylvania and a degree in economics from the École Supérieure de Commerce de Paris.